|
|
|
| Digestive Remedies in Argentina |
|
| Table of Contents Published: 2009/06 Published by: Euromonitor International |
| Euromonitor International' s Digestive Remedies in Argentina report offers a comprehensive guide to the size and shape of the market at a national level. ... |
| Analgesics in Norway |
|
| Table of Contents Published: 2009/06 Published by: Euromonitor International |
| Euromonitor International' s Analgesics in Norway report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the sectors driving growth. It id ... |
| Analgesics in Argentina |
|
| Table of Contents Published: 2009/06 Published by: Euromonitor International |
| The Argentine market for OTC healthcare products saw growth during 2008, due to higher advertising expenditure aiming to make consumers aware of the benefits of products such as Elea' s Mox 12 Hs naproxen, or Boehringer' s Buscapina Fem IBS treatment. Add ... |
| Zimbabwe Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| In the BMI Business Environment Ranking for Q309, Zimbabwe remains firmly at the bottom of the
matrix, which ranks 17 key markets surveyed in the Middle East and Africa (MEA) region, as well as
globally. Zimbabwefs position is expected to show little i ... |
| Thailand Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| In BMIfs Pharmaceutical Environment Ranking table for Q309, Thailand remains placed 10th, out of the
15 key markets surveyed in the Asia Pacific region. Thailandfs growing and ageing population and the
expansion of universal healthcare coverage repres ... |
| Slovakia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Following an update to our macroeconomic variables as a result of both the eurozone accession and
global economic downturn, BMI now expects Slovakiafs pharmaceutical expenditure to grow to
EUR2.06bn (US$2.62bn) by 2013. While this is below our previous ... |
| Singapore Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| In BMIfs Business Environment Rankings (BER) matrix for Q309, Singapore slipped from fourth to
sixth position out of the 15 key countries in the Asia Pacific region, in line with worsening economic
conditions and their impact on the pharmaceutical mark ... |
| Philippines Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| The Philippines remains ranked as the 11th most attractive pharmaceutical market among 15 major
countries in the Asia Pacific region, according to BMIfs Business Environment Rankings for Q309.
Nevertheless, BMI expects the country to improve this posit ... |
| Lebanon Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Lebanon remains a strong pharmaceutical market in the Middle East and Africa (MEA) region. In BMIfs
updated Business Environment Ratings for Q309, Lebanon holds a respectable 13th position. The
countryfs pharmaceutical market was worth US$500mn in 200 ... |
| Latvia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| BMI calculates the Latvian pharmaceutical market to have been worth LVL256mn (US$512mn) in 2008,
and by 2013, drug expenditure is expected to reach a value of LVL352mn. In US dollar terms, however,
as a result of the weakening lat, drug market spending ... |
| Kuwait Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Kuwaitfs pharmaceutical market is small in regional terms. Combined sales of over-the-counter (OTC)
and prescription drugs reached a total of US$377mn in 2008, and we expect this to reach US$462mn by
2013 ? representing a compound annual growth rate (C ... |
| Israel Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| In BMIfs updated Business Environment Rankings (BER) for Q309, Israel continued slipping down the
table, now ranking seventh out of the 17 Middle East and African (MEA) markets surveyed. While the
country scores strongly across the country structure an ... |
| Greece Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Greecefs uncontrolled growth in drug expenditure, which increased by 59% between 2004 and 2008, has
led the country to rank among the highest per capita spenders in Europe. While a proportion of this figure
is likely attributable to the countryfs para ... |
| Germany Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Germanyfs drug market expenditure reached a value of EUR40.6bn (US$59.7bn) in 2008. The value of
the countryfs pharmaceutical market is forecast to reach EUR48.6bn (US$61.6bn) by 2013, representing a
compound annual growth rate (CAGR) of 3.69% in loca ... |
| Croatia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Of the 20 markets measured in BMIfs Q309 Pharmaceuticals & Healthcare Business Environment
Rankings for Central and Eastern Europe (CEE), Croatia is placed 10th, reflecting the countryfs middleranking
attractiveness for multinational companies. While ... |
| Canada Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| For BMIfs Pharmaceutical and Healthcare Q309 Report for Canada, we believe the total drug market
value will increase from US$22.4bn in 2008 to US$37.2bn by 2013, representing a compound annual
growth rate (CAGR) of 10.7% in US dollar terms. We believe ... |
| Bangladesh Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Published by: Business Monitor International |
| Out of the 15 key markets surveyed in BMIfs Pharmaceuticals & Healthcare Business Environment
Rankings, Bangladesh is placed in 13th position, and can be found above Pakistan and Vietnam, the latter
being judged the least attractive proposition for inv ... |
| Fibromyalgia Market Forecast |
|
| Table of Contents Published: 2009/06 Published by: Datamonitor |
| Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market for all current and future brands indicated for fibromyalgia. Datamonitor forecasts the fibromyalgia market to more than ... |
| Asthma and COPD Market Forecast |
|
| Table of Contents Published: 2009/06 Published by: Datamonitor |
| Although the respiratory market has expanded considerably from 2004 to 2008, growth in the seven major markets is slowing down from 2009 to 2011, after which sales will decline due to patent expiries of leading brands. Growth is driven by the expansion of ... |
| HIV Market Forecast |
|
| Table of Contents Published: 2009/06 Published by: Datamonitor |
| In 2008, antiretroviral sales across the seven major markets totaled $10.7 billion, growing at a CAGR of 12.8% between 2005 and 2008. Datamonitor expects this expansion to slow down. Despite drivers such as new product launches, earlier treatment initiati ... |
| Cytotoxic Therapies Market Forecast |
|
| Table of Contents Published: 2009/06 Published by: Datamonitor |
| The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs' success, generic entry will ensure continued ... |
| Pharmacogenomics: Delivering on the Promise |
|
| Table of Contents Published: 2009/06 Published by: Insight Pharma Reports |
| Pharmacogenomics (PGx) is often considered the great new wave in medicine, promising better, safer, and more affordable healthcare. Yet its adoption and widespread use in the clinic is up against some tremendous challenges. ... |
| Pharmaceutical Pricing and Reimbursement in China |
|
| Table of Contents Published: 2009/06 Published by: Decision Resources, Inc. |
| With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third largest in the world in 2011. A radical healthcare reform package recently unveiled by the government will more than double public healthcare expend ... |
| The World Medical Markets Fact Book 2009 |
|
| Table of Contents Published: 2009/06 Published by: Espicom Business Intelligence |
| In today' s challenging market environment the need to understand world medical marketplaces, and be able to answer quickly those questions that arise daily, is essential. Therefore an authoritative, current and comprehensive market intelligence source is ... |
| Global In Vitro Diagnostic Market Analysis |
|
| Table of Contents Published: 2009/06 Published by: RNCOS E-Services Pvt. Ltd. |
| The In vitro diagnostics (IVD) market represents one of the most lucrative segments in the global healthcare industry. Various factors, such as increasing prevalence of several chronic and infectious diseases, emerging technologies and increasing patient ... |
|
|
|
View Cart
Top